drugset / Trial / NCT00336466
The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)
Phase 2
Completed
32 enrolled
University of Calgary
Calgary Health Region · collabOrtho Biotech, Inc. · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
Context: Neurocognitive dysfunction complicates coronary artery bypass graft surgery. Neurocognitive dysfunction is a measurable problem with thinking. Erythropoietin may be a neuroprotectant. Objective: To investigate the feasibility and safety of three doses of human recombinant erythropoietin to reduce neurocognitive dysfunction in coronary artery bypass graft patients.
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 375 iu/kg | Intravenous |
| Subject | epoetin alfa | Protein / enzyme biologic | 750 iu/kg | Intravenous |
| Subject | epoetin alfa | Protein / enzyme biologic | 1500 iu/kg | Intravenous |